entertainment -WSS

entertainment

author：hotspot 2025-09-07 14:04:03 - browse：9

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Criminal prosecution for violating HIPAA: an emerging threat

WSS

The battle over 'scope creep' and who gets to be called 'doctor'

Roche’s Alnylam deal shows drug firms interested in heart drugs

Case highlights the risks of experimental stem cell therapy

Addiction experts warn against a second 'war on drugs'

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Readout LOUD podcast: Live from STAT Breakthrough Summit West

hotspot

entertainment

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

STAT Report: Patient voices and perspectives

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The haunting brain science of long Covid

Dobbs anniversary: the lost opportunity of abortion as health care

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Duchenne breakthrough therapy leaves behind pioneering families

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Apple is now the first public company to be valued at $3 trillion

Rise in cancer among younger people worries and puzzles doctors

entertainment

Why patients can’t get everything they want on drug pricing

Senate panel puts off hardest PBM reforms for another day

The haunting brain science of long Covid

Will the FTC rein in IQVIA's health data empire?

Cytokinetics CEO stresses company can launch heart drug on its own

Military medical care influenced by rank and race, new study finds

hotspot

explore

leisure time

knowledge